Inventiva secures 21.4 million
IVA Stock | USD 2.28 0.11 4.60% |
About 62% of Inventiva's investor base is looking to short. The analysis of the overall investor sentiment regarding Inventiva Sa suggests that many traders are alarmed. The current market sentiment, together with Inventiva's historical and current headlines, can help investors time the market. In addition, many technical investors use Inventiva Sa stock news signals to limit their universe of possible portfolio assets.
Inventiva |
Inventiva raises 21.4 million for Phase III clinical trial, part of a larger equity financing of up to 348 million for lanifibranor research.
Read at seekingalpha.com
Inventiva Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Inventiva can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inventiva Fundamental Analysis
We analyze Inventiva's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inventiva using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inventiva based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Inventiva is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Inventiva Sa Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inventiva stock to make a market-neutral strategy. Peer analysis of Inventiva could also be used in its relative valuation, which is a method of valuing Inventiva by comparing valuation metrics with similar companies.
Peers
Inventiva Related Equities
HCWB | HCW Biologics | 21.82 | ||||
RZLT | Rezolute | 2.70 | ||||
PCVX | Vaxcyte | 0.92 | ||||
IPHA | Innate Pharma | 0.47 | ||||
CGEM | Cullinan Oncology | 0.37 | ||||
VTYX | Ventyx Biosciences | 0.00 | ||||
JANX | Janux Therapeutics | 0.00 | ||||
EWTX | Edgewise Therapeutics | 0.53 | ||||
NAMS | NewAmsterdam Pharma | 0.97 | ||||
ACLX | Arcellx | 1.25 | ||||
MLYS | Mineralys Therapeutics, | 2.75 | ||||
VRCA | Verrica Pharmaceuticals | 3.05 | ||||
IMCR | Immunocore Holdings | 3.88 | ||||
INBX | Inhibrx | 3.99 | ||||
CMPX | Compass Therapeutics | 4.23 | ||||
VIGL | Vigil Neuroscience | 5.78 | ||||
GLUE | Monte Rosa | 14.47 | ||||
ANEB | Anebulo Pharmaceuticals | 22.90 |
Complementary Tools for Inventiva Stock analysis
When running Inventiva's price analysis, check to measure Inventiva's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inventiva is operating at the current time. Most of Inventiva's value examination focuses on studying past and present price action to predict the probability of Inventiva's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inventiva's price. Additionally, you may evaluate how the addition of Inventiva to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |